drugset / Trial / NCT06188026

A Research Study Looking at How the Compound NNC0194-0499 Works With Birth Control Pills in Women Not Able to Bear Children.

NCT06188026

Phase 1 Completed 34 enrolled Novo Nordisk A/S
NaSequentialOpen-labelTreatment

Summary

The study will investigate the influence of NNC0194-0499 on the blood levels of the two components of a birth control pill, Microgynon®. Participants will get the birth control pill in form of tablets in two periods of 8 days each. Participants will get NNC0194-0499 as injection under the skin of their thigh. The injections will be given once weekly for 5 weeks. The study will last for about 11 to 15 weeks, depending on the length of the screening period. Participants will have to stay overnight at the study centre (2 nights and 4 nights, respectively) Only healthy women who are not able to bear children can take part in this study.

Timeline

Start
2023-12-18
Primary completion
2024-12-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 150 ug Oral
Subject ethinyl estradiol Small molecule 30 ug Oral
Subject zalfermin Protein / enzyme biologic 30 mg Subcutaneous

Indications

No indication recorded.